MAINZ BIOMED NV (MYNZ) Forecast, Price Target & Analyst Ratings
NASDAQ:MYNZ • NL0015000LC2
0.8441 USD
+0.02 (+2.07%)
At close: Mar 11, 2026
0.7836 USD
-0.06 (-7.17%)
After Hours: 3/11/2026, 7:27:32 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MAINZ BIOMED NV (MYNZ).
Forecast Snapshot
Consensus Price Target
$14.28
+ 1,591.74% Upside
Next Earnings Forecast
Release DateMar 30, 2026
PeriodQ3 / 2025
EPS Estimate-$2.04
Revenue Estimate408K
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$14.28
Upside
+ 1,591.74%
From current price of $0.84 to mean target of $14.28, Based on 7 analyst forecasts
Low
$14.14
Median
$14.28
High
$14.70
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for MYNZ. The average price target is 14.28 USD. This implies a price increase of 1591.74% is expected in the next year compared to the current price of 0.8441.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
MYNZ was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about MYNZ.
In the previous month the buy percentage consensus was at a similar level.
MYNZ was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-02-14 | Maxim Group | Initiate | Buy |
| 2024-11-25 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-04-12 | Cantor Fitzgerald | Reiterate | Neutral |
| 2024-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-21 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2023-11-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-26 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-09-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-01 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-18 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-04-27 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-30 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-16 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-10 | JonesTrading | Initiate | Buy |
| 2022-10-25 | Cantor Fitzgerald | Initiate | Overweight |
| 2022-06-21 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 30, 2026
PeriodQ3 / 2025
EPS Estimate-$2.04
Revenue Estimate408K
Revenue Q2Q33.33%
EPS Q2Q54.55%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
MYNZ is expected to report earnings on 3/30/2026. The consensus EPS estimate for the next earnings is -2.04 USD and the consensus revenue estimate is 408.00K USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 530K -8.62% | 895.5K 68.96% | 894K -0.17% | 891.48K -0.28% | 936.36K 5.03% | 2.542M 171.48% | 30.765M 1,110.27% | 75.503M 145.42% | 153.18M 102.88% | 222.78M 45.44% | 268.5M 20.52% | 318.62M 18.67% | |
| EBITDA YoY % growth | -26.13M -170.78% | -25.778M 1.35% | -17.401M 32.50% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -26.51M -172.74% | -26.645M -0.51% | -18.418M 30.87% | -17.583M 4.54% | -19.441M -10.57% | -23.365M -20.18% | -9.783M 58.13% | 18.594M 290.07% | 69.761M 275.18% | 129.61M 85.79% | 162.39M 25.29% | 262.09M 61.40% | |
| Operating Margin | -5,001.89% | -2,975.40% | -2,060.20% | -1,972.31% | -2,076.25% | -919.16% | -31.80% | 24.63% | 45.54% | 58.18% | 60.48% | 82.26% | |
| EPS YoY % growth | N/A | -48.05 31.13% | N/A 63.45% | -2.92 83.39% | -1.38 52.80% | -1.50 -8.89% | -0.04 97.28% | 0.27 750.00% | 0.66 150.00% | 0.92 38.46% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -2.04 54.55% | -2.04 44.44% |
| Revenue Q2Q % growth | 408K 33.33% | 408K 9.32% |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.17%
EPS Next 5 Year
15.04%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
32.90%
Revenue Next 5 Year
133.71%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
MAINZ BIOMED NV / MYNZ Forecast FAQ
Can you provide the average price target for MAINZ BIOMED NV stock?
7 analysts have analysed MYNZ and the average price target is 14.28 USD. This implies a price increase of 1591.74% is expected in the next year compared to the current price of 0.8441.
When does MAINZ BIOMED NV (MYNZ) report earnings?
MAINZ BIOMED NV (MYNZ) will report earnings on 2026-03-30, after the market close.
Can you provide the consensus estimates for MAINZ BIOMED NV next earnings?
The consensus EPS estimate for the next earnings of MAINZ BIOMED NV (MYNZ) is -2.04 USD and the consensus revenue estimate is 408.00K USD.
How do analysts rate MAINZ BIOMED NV (MYNZ)?
The consensus rating for MAINZ BIOMED NV (MYNZ) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.